# Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients

> **NCT06265077** · PHASE1,PHASE2 · COMPLETED · sponsor: **Noha Mansour** · enrollment: 58 (actual)

## Conditions studied

- Breast Cancer
- Filgrastim Adverse Reaction

## Interventions

- **DRUG:** Placebo
- **DRUG:** famotidine and loratadine

## Key facts

- **NCT ID:** NCT06265077
- **Lead sponsor:** Noha Mansour
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-01
- **Primary completion:** 2024-10-17
- **Final completion:** 2024-10-17
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06265077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06265077, "Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06265077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*